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Abstract
Substantial attention and resources have been directed to improving outcomes of patients with critical illnesses, in
particular sepsis, but all recent clinical trials testing various interventions or strategies have failed to detect a robust
benefit on mortality. Acute heart failure is also a critical illness, and although the underlying etiologies differ, acute
heart failure and sepsis are critical care illnesses that have a high mortality in which clinical trials have been difficult to
conduct and have not yielded effective treatments. Both conditions represent a syndrome that is often difficult to
define with a wide variation in patient characteristics, presentation, and standard management across institutions.
Referring to past experiences and lessons learned in acute heart failure may be informative and help frame research in
the area of sepsis. Academic heart failure investigators and industry have worked closely with regulators for many years
to transition acute heart failure trials away from relying on dyspnea assessments and all-cause mortality as the primary
measures of efficacy, and recent trials have been designed to assess novel clinical composite endpoints assessing
organ dysfunction and mortality while still assessing all-cause mortality as a separate measure of safety. Applying the
lessons learned in acute heart failure trials to severe sepsis and septic shock trials might be useful to advance the field.
Novel endpoints beyond all-cause mortality should be considered for future sepsis trials.
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Introduction
Sepsis, defined as "life-threatening organ dysfunction due
to a dysregulated host response to infection" [1], is a major
cause of mortality and morbidity worldwide [2–6]. Litera-
ture estimates of sepsis incidence vary widely [7]. One US
study reported an absolute incidence ranging from 300 to
1031 cases per 100,000 population [7, 8]. The annual inci-
dence of sepsis globally has been roughly estimated at 15
to 19 million [7, 9]. A systematic review of 33 studies ori-
ginating in North America, Europe, Asia, and Australia
found a population incidence for hospital-treated sepsis of
256 cases per 100,000 person-years [10]. The authors ex-
trapolated these findings to estimate a global incidence for
sepsis of 30.7 million cases, contributing to an estimated 6
million deaths each year [10].
Sepsis mortality has declined over the last decade
from ~40 to ~20 % [11]. Improved processes of care (e.g.,
earlier diagnosis; timely resuscitation with appropriate
therapies; low tidal volume during mechanical ventilation)
may explain this observation [12–15]. However, neuro-
muscular, psychological, metabolic, cardiovascular, and
renal complications persist and lead to impaired long-
term outcomes among sepsis survivors [16, 17]. In
addition, many sepsis patients are elderly and have other
life-limiting comorbidities. Survival may be less important
to these patients than measures reflecting independence
and quality of life [18]. The long-term outcome and mor-
bidity burden of sepsis survivors is an emerging, import-
ant research and clinical care concern.
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Effective therapies are needed to better manage sepsis
patients [19]. Therapeutic goals include not only im-
proving survival but also reducing morbidity, preventing
organ failure, and shortening convalescence [2, 20]. Sub-
stantial attention has been directed at reducing mortality
in sepsis, but all recent multinational trials have failed to
improve survival [21–26].
Other critical care conditions (e.g., acute heart failure)
have faced similar challenges with efforts to prolong sur-
vival in clinical trials. Acute heart failure and sepsis are
both critical care illnesses with high mortality. Both condi-
tions represent syndromes with wide variation in patient
characteristics, presentation, and standard management.
Further, the underlying pathophysiology in both condi-
tions is related to many processes, but pharmacologic
interventions generally target single pathways and have
not translated into survival benefits. All-cause mortality is
usually the primary endpoint chosen for phase 3 pivotal
trials in sepsis and acute heart failure, but no treatments
to date have effectively reduced the high mortality associ-
ated with either of these conditions (Fig. 1). In a survey of
acute heart failure experts, most felt it was unlikely that
improvements in short-term mortality could be shown as
a single primary endpoint in acute heart failure trials [27].
Thus, recent and ongoing acute heart failure trials have
been designed with composite clinical primary endpoints,
reserving all-cause mortality assessments for safety [28].
This approach recently adopted in some acute heart fail-
ure trials may help frame research in sepsis, since both of
these critical care illnesses have faced similar challenges in
clinical research.
The European Drug Development Hub brought to-
gether experts in critical care/sepsis and acute heart fail-
ure with the objective of sharing the collective clinical
research experience in these critical care illnesses. The
ultimate goal was to discuss better approaches to con-
ducting clinical trials in critical care illnesses with high
mortality (i.e., sepsis and acute heart failure) to promote
advances in the care of these patients (Paris, France,
January 2015). This paper summarizes the key develop-
ments from the meeting, focusing on clinical trial
designs and endpoints that should be considered for use
in future sepsis trials.
Review
Clinical trials in sepsis
Why have outcomes failed to improve in clinical trials?
An overview of the results from a selection of recent
large, rigorously designed and conducted sepsis clinical
trials reveals a consistent theme (Table 1). All trials were
designed with short-term all-cause mortality as the pri-
mary endpoint, but none of the interventions has im-
proved short-term survival for a variety of possible
reasons (Table 2).
Mortality rates due to sepsis are declining but remain
high [5]. Statistical power is dependent on several
parameters, including the population’s baseline risk, the
modifiable mortality, and on the treatment effect size
and its variability within the study sample. In some re-
cent sepsis trials, all-cause mortality ranged from 19 to
45 % depending on the study population and follow-up
duration (Table 1). Achieving lower than expected event
Fig. 1 In-hospital mortality rates for septicemia, respiratory failure, and acute heart failure. Acute coronary syndrome included as an example of a
critical care cardiovascular condition where reductions in in-hospital mortality have been realized. Rates are per 100 discharges for acute coronary
syndrome, septicemia, and respiratory failure and were extracted from National Hospital Discharge Survey [66–68]. Rates for acute heart failure
were based on published registry data [69] and represent percent of patients in the registries who died in the hospital. Data shown are from
ADHERE [70] and OPTIMIZE [71] (2000), EHFS II (2004) [72], ALARM (2007) [73], AHEAD (2010) [74], and ATTEND (2011) [75]. The acute heart failure
data should be interpreted considering the differences in registry populations and severity of illness
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Table 1 Overview of key recent critical care sepsis trials
Trial Design Intervention Study population Mean SOFAf
score
Endpoint Length of
follow-up
N of deaths Primary endpoint results
ALBIOS [22] Multicenter,
open-label,
randomized,
controlled
20 % albumin + crystalloid
vs. crystalloid alone for 28
days or until ICU discharge
N = 1818≥18 years,
clinical criteria for
severe sepsis [76]
Albumin 8 (6–10)
vs. crystalloid 8
(5–10)a, median
(interquartile
range)
All-cause mortality 28 days 285 albumin vs.
288 crystalloid
31.8 % albumin vs. 32 %
crystalloid (RR 1.00, 95 %
CI 0.87–1.14, P = 0.94)
SEPSISPAM [21] Multicenter,
open-label,
randomized
Vasopressor treatment
adjusted to maintain MAP
of 80–85 mmHg (high
target) vs. 65–70 mmHg
(low target) for 5 days or
until vasopressor support
weaned
N = 776Septic shock
(Table 2) refractory
to fluid resuscitation,
requiring vasopressors
Low target 10.8
± 3.1 vs. high
target 10.7 ± 3.1b
All-cause mortality 28 days 142 high target vs.
132 low target
36.6 % high target vs.
34 % low target (HR for
high target 1.07, 95 % CI
0.84–1.38, P = 0.57)
ProCESS [26] Multicenter,
randomized
Protocol-based EGDT vs.
protocol-based standard
therapy vs. usual care
N = 1341Suspected
sepsis with ≥2 criteria
for SIRS, [76] and
refractory hypotension
or serum lactate
≥4 mmol/L
Not reported All-cause in-hospital
death
60 days 92 EGDT vs. 81
standard therapy vs.
86 usual care
21 % EGDT vs. 18.2 %
standard therapy vs.
18.9 % usual care
Combined protocol-
based groups vs. usual
care RR 1.04, 95 %
CI 0.82–1.31, P = 0.83
Rosuvastatin for
ARDSe [25]
Multicenter,
randomized,
placebo-controlled,
double-blind
Enteral rosuvastatin vs.
placebo
N = 745Positive pressure
mechanical ventilation,
PaO2 to FIO2 ratio ≤300,
bilateral infiltrates on
CXR without evidence
of left atrial hypertension,
known or suspected
infection, and ≥1 criteria
for SIRS (Table 2)
Not reported All-cause mortality
before hospital
discharge home or
until study day 60
60 days 108 rosuvastatin vs.
91 placebo
28.5 % rosuvastatin vs.
24.9 % placebo;
difference 4.0 (−2.3 to
10.2), P = 0.21; enrollment
stopped prematurely for
futility
TRISS [23] Multicenter,
randomized,
parallel-group
Leuko-reduced blood
transfusion at lower (≤7
g/dL) vs. higher (≤9 g/dL)
Hgb thresholds
N = 1000ICU, fulfilled
septic shock criteria
(Table 2), Hgb ≤9 g/dL
Both groups 10
(8-12)c, median
(interquartile
range)
All-cause mortality 90 days 216 lower Hgb vs.
223 higher Hgb
43 % lower threshold vs.
45 % higher threshold
(RR 0.94, 95 % CI 0.78 to
1.09, P = 0.44)
ARISE [24] Multicenter,
randomized,
parallel-group
EGDT vs. usual care for 6 h N = 1600Suspected or
confirmed infection, ≥2
criteria for SIRS (Table 2),
refractory hypotension or
hypoperfusion, identified
in the ED within 6 h of
presentation
Not reported All-cause mortality 90 days 147 EGDT vs. 150
usual care
18.6 % EGDT vs. 18.8 %
usual care (RR 0.98, 95 %
CI 0.80 to 1.21, P = 0.9)
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Table 1 Overview of key recent critical care sepsis trials (Continued)
PROMISE [31] Pragmatic,
open, multicenter,
parallel-group,
randomized,
controlled trial
6-h EGDT resuscitation
protocol vs. usual care
N = 1260Known or
presumed infection,
≥2 SIRS criteria,
and either refractory
hypotension or
hyperlactatemia
within 6 h after ED
presentation
EGDT 4.2 ± 2.4
vs. usual care
4.3 ± 2.4d
All-cause mortality 90 days 184 EGDT vs. 181
usual care
29.5 % EGDT vs. 29.2 %
usual care (RR 1.01, 95 %
CI 0.85 to 1.20, P = 0.9)
ICU intensive care unit, MAP mean arterial pressure, EGDT early goal-directed therapy, SIRS systemic inflammatory response syndrome, CXR chest radiography, Hgb hemoglobin, ED emergency department
aIncludes subscores ranging from 0 to 4 for each of five components (respiratory, coagulation, liver, cardiovascular, and renal components), with higher scores indicating more severe organ dysfunction. The scoring
was modified by excluding the assessment of cerebral failure (the Glasgow Coma Scale), which was not performed in these patients, and by decreasing to 65 mmHg the mean arterial pressure threshold for a
cardiovascular subscore of 1, for consistency with the hemodynamic targets as defined according to the early goal-directed therapy
bIncludes subscores ranging from 0 to 4 for each of five components (circulation, lungs, liver, kidneys, and coagulation). Aggregated scores range from 0 to 20, with higher scores indicating more severe organ failure
cSubscores ranging from 0 to 4 for each of six organ systems (cerebral, circulation, pulmonary, hepatic, renal, and coagulation). The aggregated score ranges from 0 to 24, with higher scores indicating more severe
organ failure. One variable was missing for 51 patients in the higher-threshold group and for 64 in the lower-threshold group, so their values were not included
dScores range from 0 to 24, with higher scores indicating a greater degree of organ failure. The SOFA score was calculated on the basis of the last recorded data before randomization. The SOFA renal score was based
on the plasma creatinine level only and did not include urine output
eARDS acute respiratory distress syndrome
fSOFA sequential organ failure assessment
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rates in trials (e.g., due to declining overall mortality, unin-
tended enrollment of a lower-risk population, intentional
exclusion of patients with an imminent risk of death)
reduces the likelihood of identifying true treatment
effects. As the overall mortality rate declines in the
general sepsis population, the potential absolute effect
of any given treatment is attenuated, if by nothing
else, a lower fraction of modifiable mortality [19, 29].
At the same time, if baseline risk is higher than esti-
mated, more patients will be needed as the expected
treatment effect decreases (Fig. 2).
Over- or under-estimating treatment effects should be
avoided when designing clinical trials [30]. Researchers
have struggled and often over-estimated control group
mortality when planning sample size and power esti-
mates. For example, usual care group mortality rates
were over-estimated by 5.1 % in Protocolized Care for
Early Septic Shock (PROCESS) [26], 9.7 % in Sepsis and
Mean Arterial Pressure (SEPSISPAM) [21], 19.4 % in
Australasian Resuscitation in Sepsis Evaluation (ARISE)
[24], and 10.8 % in Protocolized Management in Sepsis
(ProMISE) [31], similar to previous over-estimates in
septic shock trials (Vasopressin and Septic Shock Trial
(VASST) over-estimate was 11 %) [32].
Sepsis is a complex syndrome characterized by the
interplay of many pathways and systems. Sepsis therap-
ies must either (1) control several pathways with several
interventions or (2) hit “upstream” nodes that control a
number of pathways. The treatment approach for sepsis
has ranged from inhibiting the uncontrolled, inflamma-
tory host response to enhancing the host immune re-
sponse [33]. These seemingly conflicting approaches
illustrate the complexity of the process and the signifi-
cant (and ongoing) evolution in the understanding of
sepsis pathophysiology. Analogously, the failure of posi-
tive inotropes to improve outcomes in clinical heart
failure trials [34] was initially unexpected, but it was
better understood as the knowledge of heart failure
pathophysiology evolved.
Whether sepsis treatments targeting a single aspect of
this complex syndrome could be reasonably expected to
reduce all-cause mortality is uncertain. All-cause mortal-
ity is a robust endpoint because it reflects the net benefit
of an intervention [28]. A benefit on all-cause mortality
shows that the effect of the intervention is strong
enough to overcome the influence of events on which
the treatment has no or minimal effect [28]. While
this approach works well when most deaths are dir-
ectly related to the disease being studied, it may be
less informative when heterogeneity in cause of death
is common and mortality is often attributable to fac-
tors indirectly related to the disease such as occurs in
sepsis [35].
In sepsis trials, significant patient heterogeneity exists in
time to presentation and diagnosis, organisms(s), type and
source of infection, organ involvement, degree of organ
impairment, severity of illness, location of enrollment
(e.g., emergency department vs. ICU), pre-existing condi-
tions, and differences in standard of care across institu-
tions or geographical regions (Additional file 1: Table S1)
[36]. Recent consensus definitions for sepsis and septic
shock should help to reduce this variation in future clin-
ical trials (Additional file 1: Table S1) [1, 37]. The selection
of sites participating in a clinical trial can substantially influ-
ence endpoints (e.g., variation in comorbidities or applica-
tion of background therapies can impact event rates across
high and low enrolling centers) and make interpretation of
Table 2 Reasons for lack of survival improvements in sepsis
clinical trials
• Declining mortality rates over time
• Over-estimated treatment effects
• Suboptimal pre-clinical models
• Knowledge of pathophysiology is still evolving, making
pathophysiologic targets difficult to identify
• Incorrect treatment targets
• Heterogeneity of the syndrome
• Heterogeneity of the patient population
• Improbability that a single treatment can impact key pathophysiologic
processes that influence all-cause mortality
Fig. 2 Estimated sample sizes by baseline mortality and absolute
mortality reduction. This figure examines the total sample size
needed to identify an absolute mortality reduction of 3 to 15 %
assuming three control group mortality rates (30, 20, and 10 %).
The assumptions in this figure is that power is 80 % for a two-sided
test and that 1:1 randomization will be employed (for example, a
total N of 3000 on the y-axis implies a n = 1500 in each treatment
arm). Source: author calculations (MOH)
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trial results difficult, a challenge that has been experienced
in acute heart failure trials [38]. Genetic variants also ap-
pear to influence severity [39]. Treatment responses might
vary, perhaps considerably, within such a group of patients
according to clinical and genetic heterogeneity. Recent ob-
servational cohort studies highlighted the wide variation in
mortality rates according to infection source [40]. At
present, most trials do not consider heterogeneous treat-
ment effects when estimating sample sizes. As a result, sub-
group analyses, though often employed, are likely to miss
important signals from treatments and interventions [19].
Approaches to design clinical trials in sepsis
Characterization of pathophysiology: matching the
treatment to the disease
Animal models used in sepsis do not accurately reflect
the presentation of sepsis in humans [41, 42], in large
part because there is no single presentation of sepsis in
human disease. Validated and more clinically relevant
animal models are needed to understand the disease
process and enable therapy selection targeting specific
pathophysiologic mechanisms. These models should rep-
licate the duration of clinical intensive care treatment
[42], integrate standard intensive care measures and ad-
vanced supportive care [42, 43], investigate higher order
species to minimize the physiological and immunological
differences between small animal species and humans
[44–46], and investigate older animals with chronic
comorbidities to better reflect real-world patient popula-
tions [42]. An alternate approach that might be more in-
formative is to use the heterogeneity of animal models
to understand predictors of treatment response, and
then seek to replicate the predictors in a human trial.
This approach has been explored in a systematic re-
view of anti-tumor necrosis factor (anti-TNF) animal
studies [47]. Biomarkers may play a role if they aid in
diagnosis, prognosis (e.g., troponin in acute coronary
syndrome [48] or N-terminal brain natriuretic peptide
(NT-proBNP) in heart failure [49]), or identify patient
subsets likely to respond to specific interventions (i.e.,
predictive biomarkers). Multi-biomarker approaches
may be promising [50].
Although many advances in cardiovascular medicine
were realized using the concept of large, simple trials,
moving towards precision medicine has been proposed
[51] (e.g., targeting patients with elevated systolic blood
pressure for vasodilator trials in acute heart failure [52]).
A similar approach has been suggested for sepsis trials,
with emphasis on defining pathophysiology through better
pre-clinical models, targeting drug development to spe-
cific pathophysiologic abnormalities, and selecting pa-
tients with clinical features likely to respond to a specific
therapeutic approach or who are at sufficient risk for poor
outcomes based on validated risk scores [42].
Appropriate endpoints for sepsis clinical trials: insights
from acute heart failure clinical trials
All-cause mortality
Reducing the morbidity burden in surviving patients is
an important therapeutic goal that is not reflected in an
all-cause mortality endpoint [53]. All-cause mortality is
an appropriate endpoint when the population has a sig-
nificant mortality risk and minimal competing risks and
the intervention has the potential to alter the mortality
risk. Short-term survival should predict longer-term sur-
vival with an acceptable quality of life. Sepsis satisfies
the first criterion, but it performs poorly on the others.
First, patients with sepsis die from many causes, but it is
often impossible to determine which is primary (e.g.,
renal, hepatic, pulmonary, cardiac) [33]. Death occurs
via many pathways, some of which are unrelated to the
therapy being studied and will not be impacted by the
treatment (e.g., a decision to withdraw support in many
ICU cases [2]). The “noise” of non-response can obscure
a beneficial effect on disease-specific death (i.e., the
death that the intervention is able to impact). Thus,
cause-specific mortality is a more informative endpoint
to determine the benefit of a drug or intervention,
whereas all-cause mortality is more meaningful when
information on the net benefit of an intervention (i.e.,
benefit in the context of adverse events or non-
response) is being sought [54]. In sepsis, cause-specific
mortality is difficult to define but perhaps could be
achieved in a clinical trial by increasing the “signal” (e.g.,
enrolling patients with the abnormality targeted by the
intervention and exclude patients at low risk of death)
and decreasing the “noise” (e.g., excluding patients with
competing mortality risks from conditions unrelated to
the sepsis episode). Cause-specific mortality might be
useful in sepsis trials to identify agents with a significant
treatment effect on specific components of the illness.
Similar to sepsis, patients with acute heart failure have
high short-term mortality, a factor which usually makes
mortality trials easier to conduct. However, in the case
of acute heart failure, most therapies primarily target
symptoms rather than the underlying pathophysiology
that leads to death. Additionally, acute heart failure
drugs are administered for a short-duration; both of
these factors reduce the likelihood that all-cause mortal-
ity will be influenced over the intermediate or long-term
(e.g., 180 days). Although the European Medicines
Agency guideline still specifies all-cause mortality as the
preferred primary endpoint in acute heart failure trials,
it states that symptomatic improvement might be
acceptable as a primary endpoint for short-term trials
provided mortality is not adversely affected [55]. Regula-
tory agencies have recently agreed to a primary hierarch-
ical clinical composite endpoint in an acute heart failure
trial that combines a global assessment of symptoms,
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persistent or worsening heart failure requiring an inter-
vention, and all-cause mortality assessed at 6, 24, and
48 h. Patients are categorized as improved (moderate or
marked improvement in clinical status at all planned
assessments without hospitalization for heart failure or
death), unchanged (modest improvement or worsening
in clinical status), or worsened (moderate or marked
worsening of clinical status at any planned assessment,
hospitalization for heart failure requiring intravenous or
mechanical interventions, or death). The distribution of
patients in each category is compared between treatment
groups to assess the treatment effect [56, 57]. This end-
point has the advantage of reflecting considerations that
are important to patients (both symptoms and out-
comes), and it allows for a short-term assessment of
morbidity and mortality during the period when the
pharmacologic effect is present. Importantly, long-term
all-cause mortality should still be assessed for safety, and
the study should be powered to demonstrate that long-
term mortality is not increased by a pre-specified safety
margin [52].
Regulatory agencies might consider a similar clinical
composite endpoint adapted for sepsis trials, where
endpoints describing end-organ function, need for
mechanical support, or need for other interventions are
combined with short-term mortality (ideally sepsis-
related mortality if consensus can be reached on a stand-
ard definition) as a primary endpoint, with longer-term
all-cause mortality assessed for safety. This approach
also has the advantage of reflecting relevant factors other
than survival that are important to patients. Rigorous
definitions for such endpoints are keys to ensure
consistency and to reduce bias in the results and to
ensure that the endpoint can be translated into a metric
that is important to patients.
Non-fatal endpoints
Total or ICU length of stay has been considered as an
endpoint for sepsis trials. It is relevant because ICU stays
are costly, but it is dependent on external factors that
are unrelated to drug therapy (e.g., physician judgment,
no accepted standards for discharge readiness, availabil-
ity of step-down beds, payer influence, local standards of
care). These same limitations have been recognized in
acute heart failure trials [58]. Thus, the length of stay is
unsuitable as a primary endpoint for pivotal trials,
but it can be useful as a secondary endpoint or to in-
form health technology and economic (cost/benefit)
assessments. Other problems with using non-fatal
endpoints include ascertainment bias, competing risks,
and informative dropout when comparing treatment
and control groups (i.e., patients who die cannot be
hospitalized and patients who die early have de-
creased length of stay) [19].
Organ dysfunction is a relevant endpoint for sepsis
trials. Multiple organs are impaired in sepsis [42], but all-
cause mortality is insensitive to determine which organ or
organ(s) are the primary driver of death. Conceptually,
integrating a measure of organ dysfunction into a mortal-
ity endpoint (e.g., days alive and free of organ dysfunction)
would provide a more comprehensive assessment of mor-
bidity and mortality. Organ dysfunction is theoretically a
more sensitive measure of the effect of an intervention on
progression of the sepsis syndrome, but this concept has
not yet been validated in trials. Since short-term
organ dysfunction is associated with long-term out-
come [17, 59], it is plausible that improvements in
organ function might translate into improved survival, but
this relationship has not yet been shown and the hypoth-
esis still requires confirmation. The primary value of
measuring organ dysfunction at the current time is to gain
an understanding of how an intervention impacts physi-
ology and organ function. Correlations between change in
short-term organ dysfunction and long-term sepsis-
associated morbidity could also be derived from large
robust registries that include long-term follow-up and
outcomes. If used as an endpoint, organ dysfunction
should be pre-defined in the protocol and statistical ana-
lysis plan. Ideally, consensus about how to define organ
dysfunction should be sought so that definitions are used
consistently across clinical trials.
Days alive and free from mechanical ventilation, renal
replacement therapy, or vasopressors (i.e., organ failure
free days) has also been proposed. These endpoints are
clinically meaningful, and widespread use of the Surviv-
ing Sepsis Campaign guidelines has led to more consist-
ent timing and application of life support interventions.
Nonetheless, the decision to institute supportive therap-
ies is often subjective and can be influenced by external
factors (e.g., reimbursement incentives, interactions of
various medical specialists (e.g., intensivists and nephrol-
ogists)), which introduces increased variability (i.e., ran-
dom noise) in the study and possibly bias if the study is
not blinded. Other complex issues also warrant consid-
eration, including whether patients value more event-
free days equally regardless of when they occur (e.g.,
moving from 0 to 1 day is the same/better/worse than
moving from 29 to 30 days), handling inclusion of mul-
tiple organs (i.e., are all organs of equal value or should
failure in some organs be weighted more heavily than
others), and methodology to account for pre-existing
organ dysfunction. Interventions can be effective in
preventing organ dysfunction (in patients who do not
have organ dysfunction) and/or preventing progression of
organ dysfunction (in patients who already have some
degree of organ dysfunction). An adequate organ dys-
function scoring system must capture both of these
possibilities.
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In general, there are no accepted surrogates for safety
[60], although death is not the only safety measure.
Safety is difficult to assess in sepsis trials because of the
high incidence of organ dysfunction in sepsis. Differ-
ences in organ dysfunction scores between treatment
groups could also be seen as a safety outcome (e.g., pre-
vention of organ dysfunction due to side effects of exces-
sive vasopressor doses and duration). Other events (e.g.,
anaphylaxis) might be relevant for specific drugs. Even if
a beneficial effect was shown on organ dysfunction or
other non-fatal endpoint, adequate assurance of safety
would still have to be demonstrated, either in a pivotal
clinical trial, in the entirety of the drug’s database, or
based on experience with similar drugs or interventions
[60]. Consultation with regulatory agencies is needed to
determine the size of the safety database and the confi-
dence level required to rule out an adverse effect on
mortality; these decisions are often dependent on the
severity of illness in the population studied and the spe-
cific benefit of the drug (e.g., a drug that improves a
clinically important outcome vs. a drug that improves
control of a biomarker).
Role of alternative study designs
Adaptive designs
Adaptive designs or seamless phase II/III designs have
the potential to improve the efficiency of clinical trials.
Adaptive designs can be particularly useful in fields in
which data are limited to inform trial planning assump-
tions in the areas of expected event rates, anticipated
effect sizes, heterogeneity of treatment effect, variance,
safety, or drop-outs [61, 62]. In sepsis, many uncertain-
ties exist at the time of trial design, and adaptive design
is a promising approach for both exploratory and con-
firmatory stages of drug development, especially in the
context of moving towards exploration of novel end-
points for sepsis trials. These designs are well accepted
for feasibility and early phase studies, but as experience
with their use has increased, they are becoming more
accepted for pivotal trials as well [63]. Potential chal-
lenges include maintaining confidentiality and blinding
of interim ongoing results and avoiding the introduction
of bias resulting from the adaptations [63]. Strict control
of type I error risk and understanding the potential
biases are important issues; rapid progress is being made
around these issues [64, 65].
Realistic trial simulation is the key tool to address
these challenges and advance the field. Trial simulation
of traditional and adaptive trial designs furthers under-
standing of strengths and weaknesses of proposed trial
designs and will illustrate vulnerabilities from minor
deviations to study design assumptions (e.g., event rates,
missing data).
Ideally, trial design should be a multi-step, collabora-
tive, and interactive multidisciplinary process between
scientific, clinical, and statistical domain experts to in-
crease the quality and chance of success. This concept
applies to all types of trials, but it is particularly import-
ant for adaptive design. Early interaction with regulators
is highly recommended when using adaptive designs in
the later stages of a drug development program [61, 62].
Conclusions
Sepsis is a major burden with high mortality, and the
lack of progress in identifying effective treatments is
discouraging for researchers and industry. The clinical
research challenges that have been encountered in sepsis
trials closely resemble those experienced by investigators
in acute heart failure trials. After decades of research, it
has become clear in the acute heart failure community
that the substantial patient heterogeneity contributes to
the difficulties in identifying effective therapies for the
condition. The recent consensus definitions for sepsis and
septic shock are important advances in this regard [1, 37].
Table 3 Priorities for future sepsis clinical trials
1. Develop more informative studies using animal models
2. Emphasize study of pathophysiology
3. Identify biomarkers, molecular signals, or genetic markers to identify
patients having an underlying causal process that might respond to
the specific treatment being studied
4. Develop networks of sepsis investigators experienced in clinical trial
conduct
5. Apply the recent Third International Consensus Definitions for Sepsis
and Septic Shock [1, 37] when determining eligibility criteria
6. Conduct targeted clinical trials in relatively homogeneous groups of
patients with characteristics suggestive of treatment response
7. Consider the addition of pre-specified covariate adjustment of the
primary endpoint to address the issue of heterogeneity
8. Exclude low-risk patients if appropriate for the intervention being
studied
9. Standardize care to reduce variability and random noise but not to
the extent that results are not generalizable
10. Develop realistic expectations for treatment effect and power trials
accordingly
11. Apply adaptive designs, especially when key variables are uncertain
(e.g., event rates, expected treatment effect)
12. Consider targeted primary endpoints with all-cause mortality
reserved for safety
13. Develop consensus in the field for standard trial definitions/criteria
for interventions if used as endpoints (e.g., vasopressors, mechanical
ventilation, renal replacement therapy)
14. Collaborate with regulators to modify approach to clinical trial
design in this field
15. Develop robust registries to test external validity of the results of
trials in broader patient populations
16. Discovery and development of a diagnostic that predicts a higher
chance of response to a specific intervention
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Additionally, assessing all-cause mortality alone is insuffi-
cient to fully characterize the burden of disease because it
omits important aspects of symptoms and functional sta-
tus. Academic heart failure investigators and industry have
worked closely with regulators for many years to transi-
tion acute heart failure trials away from relying on short-
term symptoms and all-cause mortality as the primary ef-
ficacy measures, and ongoing trials are assessing novel
clinical composite endpoints reflecting organ dysfunction
and mortality while still evaluating all-cause mortality as a
separate safety measure. Applying the lessons learned in
acute heart failure trials to sepsis trials might be useful to
advance the field (Table 3). Selecting high-risk patients
with clinical phenotypes considered likely to respond to
the intervention under study may help to reduce patient
heterogeneity within clinical trials and enable signals of
benefit to be more readily detected. Additionally, novel
endpoints beyond all-cause mortality should be consid-
ered for future sepsis trials.
Additional file
Additional file 1: Table S1. This table describes the definitions of sepsis
and septic shock that have been used in pivotal sepsis trials. (DOCX 21 KB)
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